Novartis AG ( (NVS) ) has released its Q4 earnings. Here is a breakdown of the information Novartis AG presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Novartis AG is a leading global healthcare company based in Switzerland, focused on developing innovative medicines in core therapeutic areas including cardiovascular, immunology, neuroscience, and oncology.
In the latest earnings report, Novartis reported a strong financial performance with significant growth in net sales and operating income, driven by high demand for its innovative medicines. The company also marked several innovation milestones with new drug approvals and positive trial results.
Key financial highlights include a 12% increase in net sales and a 22% rise in core operating income for the full year, with notable contributions from drugs like Entresto, Cosentyx, and Kesimpta. The company also achieved a 24% growth in free cash flow, underscoring its strong operational execution. Novartis has proposed a 6.1% increase in its dividend, reflecting its commitment to delivering shareholder value.
Looking ahead, Novartis anticipates continued sales growth and margin expansion, with expectations to deliver mid- to high-single-digit sales growth and high single to low double-digit growth in core operating income in 2025. The company remains focused on executing its robust pipeline and maintaining a balanced capital allocation to create sustainable value for shareholders.
